NL8007094A - Radiologische bepalingsmethode en daarvoor te gebruiken preparaten. - Google Patents
Radiologische bepalingsmethode en daarvoor te gebruiken preparaten. Download PDFInfo
- Publication number
- NL8007094A NL8007094A NL8007094A NL8007094A NL8007094A NL 8007094 A NL8007094 A NL 8007094A NL 8007094 A NL8007094 A NL 8007094A NL 8007094 A NL8007094 A NL 8007094A NL 8007094 A NL8007094 A NL 8007094A
- Authority
- NL
- Netherlands
- Prior art keywords
- solution
- indium
- radioactive
- hydroxyquinoline
- radioactivity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title description 4
- 239000000243 solution Substances 0.000 claims description 53
- 230000002285 radioactive effect Effects 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 12
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims description 10
- 229960003540 oxyquinoline Drugs 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000012857 radioactive material Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000000941 radioactive substance Substances 0.000 claims description 2
- INKYBOIVKCTYGX-UHFFFAOYSA-N indium;quinolin-8-ol Chemical compound [In].C1=CN=C2C(O)=CC=CC2=C1 INKYBOIVKCTYGX-UHFFFAOYSA-N 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 238000002372 labelling Methods 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 14
- 229910052738 indium Inorganic materials 0.000 description 14
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 14
- 206010000269 abscess Diseases 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000013522 chelant Substances 0.000 description 12
- 241000283707 Capra Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 10
- 229940055742 indium-111 Drugs 0.000 description 10
- 239000012503 blood component Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- AEGSYIKLTCZUEZ-UHFFFAOYSA-K tri(quinolin-8-yloxy)indigane Chemical compound [In+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 AEGSYIKLTCZUEZ-UHFFFAOYSA-K 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 ethanol Chemical compound 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002471 indium Chemical class 0.000 description 1
- 229910003437 indium oxide Inorganic materials 0.000 description 1
- PJXISJQVUVHSOJ-UHFFFAOYSA-N indium(iii) oxide Chemical class [O-2].[O-2].[O-2].[In+3].[In+3] PJXISJQVUVHSOJ-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/108,575 US4348375A (en) | 1979-12-31 | 1979-12-31 | Radioassay process and compositions useful therein |
| US10857579 | 1979-12-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8007094A true NL8007094A (nl) | 1981-08-03 |
Family
ID=22322962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8007094A NL8007094A (nl) | 1979-12-31 | 1980-12-30 | Radiologische bepalingsmethode en daarvoor te gebruiken preparaten. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4348375A (es) |
| JP (2) | JPS56103118A (es) |
| AT (1) | AT368889B (es) |
| BE (1) | BE886930A (es) |
| CA (1) | CA1155372A (es) |
| CH (1) | CH652308A5 (es) |
| DE (1) | DE3049533A1 (es) |
| DK (1) | DK556880A (es) |
| ES (1) | ES498236A0 (es) |
| FR (1) | FR2474314A1 (es) |
| GB (1) | GB2066664B (es) |
| IT (1) | IT1193721B (es) |
| NL (1) | NL8007094A (es) |
| SE (1) | SE451798B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443426A (en) * | 1982-06-14 | 1984-04-17 | Yale University | Blood agent |
| AU580958B2 (en) * | 1983-07-07 | 1989-02-09 | Mallinckrodt, Inc. | Sterile radioactive indium-containing aqueous solution |
| US4672028A (en) * | 1984-05-23 | 1987-06-09 | Icn Micromedic Systems, Inc. | Compositions and method for simultaneous multiple array of analytes using radioisotope chelate labels |
| US5376356A (en) * | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| US5792444A (en) * | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
| US5524622A (en) * | 1994-09-20 | 1996-06-11 | Oregon Health Sciences University | Non-invasive method of determining inflammation of the gastrointestinal tract |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017596A (en) * | 1975-03-03 | 1977-04-12 | Research Corporation | Radiopharmaceutical chelates and method of external imaging |
| CA1070695A (en) * | 1975-09-02 | 1980-01-29 | Michael D. Loberg | Iminodiacetic acid pharmaceutical |
| FR2390408A1 (fr) * | 1977-05-11 | 1978-12-08 | Philips France | Procede de marquage par un isotope radioactif d'un sel hydrosoluble d'oxine, ou de ses derives halogenes ou sulfones, produits ainsi marques, procede de marquage des elements figures du sang, et medicaments ainsi obtenus |
| US4335095A (en) * | 1979-03-21 | 1982-06-15 | The Radiochemical Centre Limited | Indium-111 oxine complex composition |
-
1979
- 1979-12-31 US US06/108,575 patent/US4348375A/en not_active Expired - Lifetime
-
1980
- 1980-12-30 CH CH9649/80A patent/CH652308A5/de not_active IP Right Cessation
- 1980-12-30 FR FR8027815A patent/FR2474314A1/fr active Granted
- 1980-12-30 IT IT69013/80A patent/IT1193721B/it active
- 1980-12-30 ES ES498236A patent/ES498236A0/es active Granted
- 1980-12-30 CA CA000367724A patent/CA1155372A/en not_active Expired
- 1980-12-30 DK DK556880A patent/DK556880A/da not_active Application Discontinuation
- 1980-12-30 NL NL8007094A patent/NL8007094A/nl not_active Application Discontinuation
- 1980-12-30 SE SE8009185A patent/SE451798B/sv not_active IP Right Cessation
- 1980-12-30 AT AT0635880A patent/AT368889B/de not_active IP Right Cessation
- 1980-12-30 GB GB8041472A patent/GB2066664B/en not_active Expired
- 1980-12-31 BE BE0/203373A patent/BE886930A/fr not_active IP Right Cessation
- 1980-12-31 DE DE19803049533 patent/DE3049533A1/de not_active Withdrawn
- 1980-12-31 JP JP18946780A patent/JPS56103118A/ja active Pending
-
1989
- 1989-04-04 JP JP1084140A patent/JPH02117623A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES8202154A1 (es) | 1982-01-01 |
| DE3049533A1 (de) | 1981-09-17 |
| CH652308A5 (de) | 1985-11-15 |
| FR2474314B1 (es) | 1984-10-05 |
| SE451798B (sv) | 1987-11-02 |
| IT8069013A0 (it) | 1980-12-30 |
| ES498236A0 (es) | 1982-01-01 |
| IT1193721B (it) | 1988-08-24 |
| US4348375A (en) | 1982-09-07 |
| JPS56103118A (en) | 1981-08-18 |
| CA1155372A (en) | 1983-10-18 |
| GB2066664A (en) | 1981-07-15 |
| JPH02117623A (ja) | 1990-05-02 |
| BE886930A (fr) | 1981-04-16 |
| GB2066664B (en) | 1984-06-20 |
| DK556880A (da) | 1981-07-01 |
| FR2474314A1 (fr) | 1981-07-31 |
| AT368889B (de) | 1982-11-25 |
| ATA635880A (de) | 1982-04-15 |
| SE8009185L (sv) | 1981-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Calne et al. | Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A | |
| Riba et al. | Imaging experimental infective endocarditis with indium-111-labeled blood cellular components. | |
| GB1594187A (en) | Diagnostic agents containing albumin and methods for making same | |
| Oliver et al. | Cellular mechanisms of protein metabolism in the nephron: VII. The characteristics and significance of the protein absorption droplets (hyaline droplets) in epidemic hemorrhagic fever and other renal diseases | |
| US4443426A (en) | Blood agent | |
| Graziano et al. | A simple technique for preparation of young red cells for transfusion from ordinary blood units | |
| Thakur et al. | Simplified and efficient labeling of human platelets in plasma using indium-111-2-mercaptopyridine-N-oxide: preparation and evaluation | |
| NL8007094A (nl) | Radiologische bepalingsmethode en daarvoor te gebruiken preparaten. | |
| GERSHON et al. | Histochemical and radioautographic studies of serotonin and parafollicular cells in the thyroid gland of the prehibernating bat | |
| Draper et al. | Biochemical and structural changes in RBCs stored with different plasticizers: the role of hexanol | |
| Morrison et al. | Antigenic relationship between blood platelets and vascular endothelium | |
| Walker et al. | The greater omentum as a site of antibody synthesis | |
| NL8006869A (nl) | Radiologische bepalingsmethode in vivo. | |
| Bergmann et al. | Detection of cardiac transplant rejection with radiolabeled lymphocytes. | |
| Johnsson et al. | Ex vivo PKH26‐labelling of lymphocytes for studies of cell migration in vivo | |
| Thakur et al. | Evaluation of indium-111-2-mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation | |
| Vogt et al. | Immediate and delayed nephrotoxic nephritis in rats: The role of complement fixation | |
| Buckner et al. | Aplastic anemia treated by marrow transplantation. | |
| Chapman-Andresen | Measurement of material uptake by cells: pinocytosis | |
| Goedemans et al. | Diagnostic compositions containing a chelate of radioactive indium and 8-hydroxyquinoline | |
| Joist et al. | Methodologic and basic aspects of indium-111 platelets | |
| US4705678A (en) | Sterile radioactive indium-containing aqueous solution | |
| Thakur | Immunoscintigraphic imaging of inflammatory lesions: preliminary findings and future possibilities | |
| Roome et al. | The polyvinyl alcohols as blood substitutes | |
| Ebbe et al. | Uptake of indium-111-labeled platelets and indium-111 oxine by murine kidneys after total-body irradiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: MALLINCKRODT DIAGNOSTICA (HOLLAND) B.V. |
|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |